Botensilimab/Balstilimab Presents Clinical Responses In Refractory Sarcomas At ESMO 2024
Portfolio Pulse from Benzinga Newsdesk
Botensilimab and Balstilimab have shown promising clinical responses in treating refractory sarcomas, as presented at ESMO 2024. The combination demonstrates broad and durable activity in advanced sarcoma patients.
September 13, 2024 | 2:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Agenus Inc.'s Botensilimab and Balstilimab have shown promising results in treating refractory sarcomas, indicating potential positive impacts on the company's stock price.
The presentation of positive clinical responses for Botensilimab and Balstilimab in refractory sarcomas at ESMO 2024 suggests a potential increase in investor confidence and interest in Agenus Inc., likely leading to a positive short-term impact on its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90